Phase I Study of mTOR Inhibitor RAD001 in Combination With IGF-1R Inhibitor AMG479 for Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 12 May 2017
At a glance
- Drugs Everolimus (Primary) ; Ganitumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 09 May 2017 Status changed from active, no longer recruiting to completed.
- 31 Jan 2017 Planned End Date changed from 1 Dec 2016 to 31 May 2020.
- 31 Jan 2017 Planned primary completion date changed from 1 Jan 2015 to 31 May 2020.